

CITATION REPORT

List of articles citing

Cicatricial ectropion in a patient treated with dupilumab

DOI: 10.1016/j.ajoc.2017.06.017

American Journal of Ophthalmology Case Reports,
2017, 7, 120-122.

Source: <https://exaly.com/paper-pdf/67163384/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
54	Vertical-to-Horizontal Rotational Myocutaneous Flap for Repairing Cicatricial Lower Lid Ectropion: A Novel Surgical Technique. <i>BioMed Research International</i> , 2017 , 2017, 8614580	3	2
53	Cicatrizing Blepharoconjunctivitis Occurring During Dupilumab Treatment and a Proposed Algorithm for Its Management. <i>JAMA Dermatology</i> , 2018 , 154, 1485-1486	5.1	20
52	Treatment of Atopic Dermatitis with Biologic Drugs. <i>Dermatology and Therapy</i> , 2018 , 8, 527-538	4	26
51	Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis. <i>JAMA Dermatology</i> , 2018 , 154, 1208-1211	5.1	72
50	[Risk of conjunctivitis associated with dupilumab (Dupixent)]. <i>Annales De Dermatologie Et De Venereologie</i> , 2018 , 145, 556-558	0.3	2
49	Cyclosporine 0.1% (Ikervis) treatment in steroid-dependent dupilumab-associated conjunctivitis. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2019 , 94, 396-399	0.1	
48	Ocular Co-Morbidities of Atopic Dermatitis. Part II: Ocular Disease Secondary to Treatments. <i>American Journal of Clinical Dermatology</i> , 2019 , 20, 807-815	7.1	7
47	Dupilumab-associated blepharoconjunctivitis. <i>American Journal of Ophthalmology Case Reports</i> , 2019 , 16, 100550	1.3	7
46	Dupilumab side effect in a patient with atopic dermatitis: a case report study. <i>Biologics: Targets and Therapy</i> , 2019 , 13, 79-82	4.4	13
45	Pathomechanism of dupilumab-associated inflammatory eye symptoms. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, e435-e436	4.6	9
44	Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis. <i>Ophthalmology and Therapy</i> , 2019 , 8, 485-490	5	34
43	Interdisziplinäre Handlungsempfehlung bei Dupilumab-assoziierten entzündlichen Augenerkrankungen. <i>Hautnah</i> , 2019 , 18, 33-35	0.2	
42	Management of ocular allergy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019 , 74, 1611-1630	9.3	30
41	Conjunctivitis in dupilumab clinical trials. <i>British Journal of Dermatology</i> , 2019 , 181, 459-473	4	147
40	A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis. <i>Drugs in R and D</i> , 2019 , 19, 311-318	3.4	21
39	Investigating the role of allergic contact dermatitis in residual ocular surface disease on dupilumab (ROSDD). <i>International Journal of Womens Dermatology</i> , 2019 , 5, 308-313	2	8
38	Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): A novel case report. <i>JAAD Case Reports</i> , 2019 , 5, 34-36	1.4	21

37	[Interdisciplinary recommendations for action in dupilumab-related inflammatory eye diseases]. <i>Hautarzt</i> , 2019 , 70, 64-67	1.1	6
36	Association of Blepharitis and Ectropion With Tumor Necrosis Factor β Inhibitor Treatment in Crohn Disease. <i>JAMA Ophthalmology</i> , 2019 , 137, 232-233	3.9	2
35	Two differing presentations of periocular dermatitis as a side effect of dupilumab for atopic dermatitis. <i>Orbit</i> , 2019 , 38, 390-394	1.5	16
34	Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. <i>British Journal of Ophthalmology</i> , 2020 , 104, 776-779	5.5	21
33	Punctal stenosis associated with dupilumab therapy for atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2021 , 32, 737-740	2.8	3
32	Dupilumab-Induced Bilateral Cicatricial Ectropion in Real Life. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020 , 8, 728-729	5.4	5
31	Dupilumab-Associated Blepharoconjunctivitis with Giant Papillae. <i>International Medical Case Reports Journal</i> , 2020 , 13, 303-305	1	2
30	A Practical Approach to Recalcitrant Face and Neck Dermatitis in Atopic Dermatitis. <i>Dermatitis</i> , 2020 , 31, 169-177	2.6	14
29	Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. <i>Clinical Microbiology Reviews</i> , 2020 , 33,	34	32
28	Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents. <i>Paediatric Drugs</i> , 2020 , 22, 295-310	4.2	32
27	Dupilumab-Associated Mucin Deficiency (DAMD). <i>Translational Vision Science and Technology</i> , 2020 , 9, 29	3.3	12
26	Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 172-179	4.6	12
25	Additional Biologic Therapeutics. 2021 , 339-348.e4		1
24	Drugs Used to Treat Allergic and Neuromuscular Disorders. 2021 , 285-297		
23	Association of Dupilumab with Intraocular Inflammation. <i>Ocular Immunology and Inflammation</i> , 2021 , 1-6	2.8	1
22	Prevalence of ocular disease during dupilumab treatment for atopic dermatitis: a bicentric retrospective comparative cohort study. <i>International Journal of Dermatology</i> , 2021 , 60, 1520-1528	1.7	0
21	Safety of dupilumab in patients with atopic dermatitis: expert opinion. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 997-1004	4.1	0
20	Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2021 ,	4.5	8

19	Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase. <i>Scientific Reports</i> , 2021 , 11, 14293	4.9	0
18	Complications oculaires induites par le dupilumab au cours du traitement de la dermatite atopique. <i>Revue Francaise D'allergologie</i> , 2021 , 61, 592-592	0.2	
17	Dupilumab-induced ocular surface disease: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2021 ,	4.5	0
16	A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis.. <i>JID Innovations</i> , 2021 , 1, 100042		2
15	Punctal Stenosis a Rare Complication of Dupilumab Therapy for Atopic Dermatitis: A New Case Report. <i>Journal of Cosmetics Dermatological Sciences and Applications</i> , 2021 , 11, 96-100	0.2	
14	Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae. <i>Eye</i> , 2021 , 35, 3277-3284	4.4	10
13	Cyclosporine 0.1% (Ikervis) treatment in steroid-dependent dupilumab-associated conjunctivitis. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2019 , 94, 396-399	0.5	4
12	Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis. <i>Cornea</i> , 2020 , 39, 784-786	3.1	10
11	Painless thyroiditis in a dupilumab-treated patient. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2020 , 2020,	1.4	2
10	Dupilumab-associated ocular surface disease: incidence, management and long-term sequelae.		1
9	Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review.. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022 ,	4.6	0
8	Dupilumab-associated ocular manifestations: A review of clinical presentations and management.. <i>Survey of Ophthalmology</i> , 2022 ,	6.1	0
7	Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases.. <i>Clinical Reviews in Allergy and Immunology</i> , 2022 , 1	12.3	0
6	Dupilumab-associated cicatrizing ocular disease.. <i>American Journal of Ophthalmology Case Reports</i> , 2022 , 26, 101528	1.3	0
5	Characterising the chronicity of dupilumab-associated ocular surface disease: an analysis of a retrospective case series. <i>BMJ Open Ophthalmology</i> , 2022 , 7, e000947	3.2	0
4	Effects of systemic targeted immunosuppressive therapy on ocular surface. <i>Current Opinion in Ophthalmology</i> , Publish Ahead of Print,	5.1	
3	Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting.		0
2	Dupilumab-associated ectropion and punctal stenosis treated with tacrolimus ointment (0.03%) in a 15-year-old girl. 2022 ,		0

- 1 Effectiveness and safety of dupilumab in adults with moderate and severe atopic dermatitis in Colombia: Real-life experience. **2023**, 16, 100763

o